Rating Change
Guggenheim analysts initiated coverage on Kazia Therapeutics Limited (NASDAQ:KZIA) with a rating of Buy on October 21, 2026.
new coverageNASDAQ:KZIA
Guggenheim Initiates Coverage on Kazia Therapeutics Limited (KZIA) with Buy
Guggenheim analysts initiated coverage on Kazia Therapeutics Limited (NASDAQ:KZIA) with a rating of Buy on October 21, 2026.
At publication ·
What changed
Kazia Therapeutics Limited (NASDAQ:KZIA) · new coverage
- Firm
- Guggenheim
- Rating
- Buy
- Price at event
- $8.18
- Market capitalization
- $21.2M
At a glance
Key takeaways
- Guggenheim initiated Buy coverage on Kazia Therapeutics (KZIA) on October 21, 2026, with the stock trading at $8.18 and a market cap of $21.2 million.
Market Context
Kazia Therapeutics Limited operates in the Healthcare sector. The stock currently trades at $8.18 with a market capitalization of $21.2M. The stock has gained 12.3% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kazia Therapeutics Limited.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Kazia Therapeutics Limited
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 21, 2026 | Guggenheim | Buy | N/A |
| Oct 20, 2026 | Leerink Partners | Outperform | N/A |
| Sep 10, 2026 | BTIG | Buy | N/A |
| Sep 01, 2026 | BTIG | Buy | N/A |
| Aug 13, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KZIA Stock Page
Frequently Asked Questions
What does the Buy rating mean for KZIA?
A rating of Buy from Guggenheim reflects the analyst's outlook on Kazia Therapeutics Limited (NASDAQ:KZIA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KZIA forecast page.